Background Epstein-Barr virus (EBV) is strongly implicated in the development of multiple sclerosis (MS) but whether ...
Background Machine learning (ML) models have been proposed to improve the discrimination of intracranial aneurysm rupture status beyond established clinical risk stratification tools. However, ...
Background To compare relapse and disability outcomes of inebilizumab, azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) in maintenance-therapy-naive patients with aquaporin-4 ...
Background Myotonic dystrophy type 2 (DM2) is a frequent yet underdiagnosed muscle disorder. Although muscle MRI is ...
Background Evidence regarding the clinical course of unruptured giant intracranial aneurysms (GIAs) after conservative management (CON), microsurgical treatment (SURG) or endovascular treatment (EVT) ...
Register studies (Wimberly et al) reveal the long-lasting educational disadvantage of childhood epilepsy but unexpected sex differences indicate that the mechanisms require cautious interpretation.
Background To investigate whether exposure to pet hamsters may act as a potential trigger for autoimmune cerebellar ataxia (ACA). Methods We conducted a hospital-based case–control study based on our ...
Focused ultrasound (FUS) is an emerging technology that uses ultrasound waves to ablate or modulate tissue. While it has been explored in several different clinical fields for over two decades, it has ...
Background The pathogenic mechanisms underlying autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy (GFAP-A), a central nervous system disorder associated with GFAP autoimmunity, remain ...
Background Plasma phosphorylated tau (p-tau) 217 test has emerged as a minimally invasive and accessible alternative to positron emission tomography imaging and cerebrospinal fluid analysis for ...
Myasthenia gravis (MG) treatment’s landscape has dramatically changed with the approval of novel therapeutics that can provide rapid improvement, including in patients typically considered refractory.
Background The effectiveness of disease-modifying therapies (DMTs) in multiple sclerosis (MS) declines with age, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results